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Background: Vitamin D is hypothesized to prevent periodontal disease progression through its
immune-modulating properties and its role in maintaining systemic calcium concentrations. The authors
investigated associations between plasma 25-hydroxyvitamin D [25(OH)D] (collected 1997 to 2000) and
the 5-year change in periodontal disease measures from baseline (1997 to 2000) to follow-up (2002 to
2005) among 655 postmenopausal women in a Women’s Health Initiative Observational Study ancillary
study. Exploratory analyses were conducted in 628 women who also had 25(OH)D measures at follow-
up.
Methods: Four continuous measures of the 5-year change in periodontal disease were assessed using
alveolar crest height (ACH), clinical attachment level (CAL), probing depth (PD), and percentage of gin-
gival sites that bled on assessment. Linear regression was used to estimate b-coefficients, standard
errors, and P values corresponding to change in periodontal disease (a 1-mm change in ACH, CAL,
or PD or a 1-unit change in the percentage of gingival sites that bled) for a 10-nmol/L difference in
25(OH)D. Models were adjusted for age, education, dental visit frequency, smoking, diabetes status, cur-
rent medications affecting bone health, baseline measures of periodontal disease, body mass index, and
recreational physical activity.
Results: No statistically significant associations were observed between baseline 25(OH)D and change
in periodontal disease measures, overall or in a subset (n = 442) of women with stable 25(OH)D concen-
trations [25(OH)D change <20 nmol/L from baseline to follow-up]. Results also did not vary significantly
in analyses that were stratified by baseline periodontal disease status.
Conclusions: No association between baseline 25(OH)D and the subsequent 5-year change in peri-
odontal disease measures was observed. Vitamin D status may not influence periodontal disease progres-
sion. More studies are needed to confirm these results. J Periodontol 2014;85:1321-1332.
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P
eriodontal disease is a common chronic, in-
flammatory disease of aging which, if not con-
trolled, can lead to tooth loss. It is estimated that
8.7%, 30.0%, and 8.5% of the United States pop-
ulation aged >30 years1 have mild, moderate, and
severe disease, respectively, based on a full-mouth
periodontal examination and the current Centers for
Disease Control and Prevention and the American
Academy of Periodontology (CDC/AAP) definition.2
Among those aged 50 to 64 and ‡65 years, preva-
lence of any periodontal disease is estimated to be
even higher, approximately 57% and 70% of the
population, respectively.1 Modifiable factors that re-
duce development and progression of periodontal
disease are of interest to the general public and to
dental professionals who want to reduce the burden
of tooth loss.
Vitamin D status has been hypothesized to prevent
and reduce the progression of periodontal disease.3
In the last decade, research has focused on vitamin D
as a potential anti-inflammatory4 and antimicrobial
agent.5 Vitamin D is also essential in maintaining
bone health and mineralization,6 presumably inclu-
sive of alveolar bone. In a cross-sectional analysis
using data from postmenopausal women enrolled
in the Buffalo Osteoporosis and Periodontal Dis-
ease (OsteoPerio) Study, an ancillary study of the
Women’s Health Initiative Observational Study, the
present authors previously showed that vitamin D
status, assessed with plasma concentrations of 25-
hydroxyvitamin D [25(OH)D], was associated with
clinical measures of oral health.7 Women with 25
(OH)D concentrations ‡50 nmol/L compared to <50
nmol/L had reduced odds of gingival bleeding (a
measure of gingival inflammation) and reduced
odds of moderate-to-severe periodontitis, assessed
using the CDC/AAP definition. However, vitamin D
status was not significantly associated with radio-
graphic measures of alveolar crest height (ACH),
which tend to reflect the chronic phase of destructive
periodontitis.
Most,7-12 although not all,13 previous cross-
sectional and case-control studies have supported
vitamin D status as a potential modifiable risk factor
for periodontal disease. Few studies14-18 have ex-
amined associations between vitamin D status and
periodontal disease measures taken over time.
Garcia et al.14 conducted a 1-year study of 51 pa-
tients with moderate-to-severe chronic periodontal
disease attending a periodontal disease maintenance
program. Patients who reported baseline use of
calcium and vitamin D supplements compared with
non-users had less periodontal disease (consider-
ing collectively a number of clinical measures) at
baseline, 6 months, and 12 months, although re-
sults were not statistically significant at 12 months.
In a larger epidemiologic study of 550 men, Krall15
found no association between self-reported base-
line intake of vitamin D from foods and supple-
ments and 7-year progression in alveolar bone
loss. In another study of 562 men, Alshouibi
et al.17 used a repeated-measures cross-sectional
design to examine associations between vitamin D
intake and periodontal disease collected one to
four times from 1986 to 1998. Vitamin D intake
was associated with lower odds of moderate-to-
severe periodontal disease. However, these studies
did not consider sunlight exposure as a source of
vitamin D when assessing vitamin D status. Vita-
min D can be synthesized in the skin on exposure
to ultraviolet B radiation.19 A recently published
study by Jimenez et al.18 showed that higher pre-
dicted 25(OH)D concentrations were associated
with a lower incidence of self-reported tooth loss in
a 20-year prospective cohort of men. That study
was limited by its use of a predictor score, instead of
direct measures of the biomarker 25(OH)D, to as-
sess vitamin D status. Jimenez et al.18 also relied on
self-reported incident periodontal disease outcomes
instead of clinical measures of disease progression.
One randomized clinical trial of 145 men and
women, nested within a larger clinical trial of bone
loss of the hip, found that supplementation of vita-
min D (700 IU/day) and calcium (500 mg/day) was
associated with decreased odds of tooth loss over 3
years (27% of the placebo group versus 13% of the
supplemented group lost ‡1 tooth).16 However, that
trial examined supplementation with both calcium
and vitamin D together, limiting the ability to dif-
ferentiate if both or just one nutrient was influential.
The purpose of this paper is to build on the cur-
rently published cross-sectional analyses in the
OsteoPerio Study.7 The authors previously ob-
served that adequate compared to inadequate or
deficient vitamin D status was associated with re-
duced odds of periodontal disease;7 however,
temporality could not be determined from that
cross-sectional study. The authors had the ability to
examine prospective associations between base-
line plasma 25(OH)D and the 5-year change in
periodontal disease measures inclusive of clinical
attachment level (CAL), probing depth (PD), ACH,
and percentage of gingival sites that bled on as-
sessment in the OsteoPerio Study, a well-defined
cohort of postmenopausal women. The biomarker
25(OH)D reflects contribution from all three sour-
ces of vitamin D: diet, supplements, and sunlight.
The authors hypothesized that baseline plasma 25
(OH)D concentrations would be inversely associ-
ated with changes in periodontal disease measures,
reflecting progression of disease during 5 years of
follow-up.




As previously described,7 1,362 women (aged 50 to
79 years) participated in the baseline OsteoPerio
Study conducted from 1997 to 2000. Of them,
five women were missing data on the study base-
line questionnaires. An additional 39 women were
missing data on ‡1 baseline periodontal disease
measure (ACH [n = 16], CAL [n = 20], PD [n = 19],
gingival bleeding measures [n = 13]). Of the re-
maining 1,318 women, baseline plasma sample
collection was implemented after the study began,
and samples were available for 25(OH)D assays in
921 women. One additional woman was excluded
because her baseline 25(OH)D was determined to be
an extreme value (530 nmol/L). Of the remaining
920 women, 675 (73%) attended the follow-up exam
(2002 to 2005) and had the follow-up periodontal
disease measures needed to compute change in
disease with time. Additionally, participants in this
longitudinal sample were excluded if they were
missing data on pertinent risk factors measured at
baseline (education [n = 10] and physical activity [n =
10]). This left a final analytic sample of n = 655. All
participants signed informed consent. The study
protocol was approved by the University at Buffalo’s
Health Sciences Institutional Review Board, and the
study was conducted in accordance with the Helsinki
Declaration of 1975, as revised in 2000.
Study Visit
These 655 study participants attended a clinic visit at
baseline (1997 to 2000) and follow-up 5 years later
(2002 to 2005). Before the study visits, participants
completed questionnaires to assess their demo-
graphic information, family and medical history,
lifestyle habits including physical activity, osteopo-
rosis risk factors, oral health history, and current
medication and supplement use. At the clinic visit,
questionnaires were reviewed for completeness,
physical measurements were taken to assess weight
and height, and participants underwent dual-energy
x-ray absorptiometry§ to determine systemic bone
mineral density (BMD). BMD was used to define
worst-site T score using all skeletal sites mea-
sured20,21 for assessment of osteoporosis status:
normal, T ‡-1.0; osteopenia, -2.5 > T <-1.0; oste-
oporosis, T £-2.5).
Oral Health Exam Outcome Measures at Baseline
and Follow-Up
Full-mouth oral clinical examinations were con-
ducted by trained and calibrated dental examiners
using standardized protocols, the details of which
were described previously.7,20,21 Measures of ACH,
PD, CAL, and gingival bleeding were assessed at
baseline and follow-up and are described in detail
elsewhere.7,20-22 ACH, in millimeters, was assessed
using standardized intraoral radiographsi and mea-
sured mesially and distally for each tooth present
(excluding third molars and canines) for a maximum
of 48 sites. The average ACH of all sites measured is
referred to as the whole-mouth mean ACH. Using
whole-mouth mean ACH levels and self-reported
tooth loss due to periodontitis, participants were
grouped into three categories of periodontal disease:
none, mild/moderate, or severe.20 A constant-force
electronic periodontal probing system¶ was used to
measure PD, in millimeters, on six surfaces of each
tooth, and the corresponding CAL, in millimeters,
was determined for each surface site assessed with
the use of a manual periodontal probe.# Measures
of whole-mouth mean PD and CAL level were
computed. Women were also categorized as having
none/mild, moderate, or severe periodontal disease
using the CDC/AAP Working Group definition.23
Gingival bleeding was assessed by inserting the
same manual type periodontal probe approximately
2 mm into the gingival sulcus/pocket at three gin-
gival sites per tooth, except third molars. Each site
was scored either 0 (absence) or 1 (presence) for
bleeding. The mean of all gingival bleeding scores
was computed, representing the proportion of all
sites assessed that bled in the mouth (when multi-
plied by 100, this represents the percentage of
bleeding sites in a mouth).
Measure of 5-Year Change in Periodontal Disease
Using the periodontal disease measures taken at
baseline and follow-up, the authors defined contin-
uous measures of 5-year change in periodontal dis-
ease (follow-up value - baseline value), with positive
values representing loss in alveolar bone and clinical
attachment, worsening of PD with time, or a greater
percentage of gingival sites that bled with time
(Table 1). In every case, change was computed from
all available 5-year measurements and their corre-
sponding measurements at baseline. For ACH, the
change at each site was determined using overlaid
oral radiographs taken at the two time periods.
Change measures from all sites were averaged, and
this is referred to as the ACH side-by-side mean
change. This method was developed by Hausmann
et al.24 and described as used in this study by
LaMonte et al.21 The whole-mouth mean change for
CAL and PD and the change in the percentage of all
gingival sites in the mouth that bled on assessment
were determined by subtracting the whole-mouth
mean CAL/PD or the percentage of bleeding sites at
baseline from the follow-up values.
§ QDR-4500A, Hologic, Bedford, MA.
i Bennett HFQ 300, Bennett X-Ray, Copiague, NY.
¶ The Florida Probe System, Florida Probe, Gainesville, FL.
# Michigan O periodontal probe, Hu-Friedy, Chicago, IL.
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Assessment of Plasma 25-(OH)D
Blood draws were conducted on the same day as
the clinical periodontal examinations. Assessment of
plasma 25(OH)D at baseline and follow-up has been
previously reported.25 Assays were conducted during
a consistent 4-month period using a competitive
chemiluminescence immunoassay.** Using the in-
vestigators’ masked, duplicate quality control sam-
ples nested in each batch, the within-pair coefficient
of variation was 4.9%. Only a subset of the sample
(n = 628) had 25(OH)D measures at follow-up. For
both baseline and follow-up 25(OH)D measures,
values were adjusted for season of blood draw using
the residual method. Residuals were computed from
regression of 25(OH)D on the day of the year of blood
draw and added back to the sample mean as pre-
viously described.7
Statistical Analyses
Data were analyzed with statistical software.†† To
better understand how loss to follow-up may have in-
fluenced the results, the authors compared charac-
teristics of study participants included in the current
prospective analysis (n = 655) to study participants
who had baseline plasma 25(OH)D concentrations
but were not included in the current analyses be-
cause they did not attend follow-up, did not have
periodontal disease measures needed to compute
change measures, or were missing data on pertinent
covariates (n = 265). Next, in the current analytic
sample of 655 women, summary measures of peri-
odontal change variables were described (Table 1)
and mean baseline plasma 25(OH)D was described
according to participant characteristics and peri-
odontal disease risk factors (Table 2). Differences
in means were examined using analysis of vari-
ance, and differences among categorical vari-
ables were examined using x2 tests. Tests were
considered statistically significant with P values of
<0.05 (two-sided).
Scatter plots of periodontal disease change mea-
sures on baseline 25(OH)D concentrations were
examined, and assumptions for statistical methods
were checked and met. In the full analytic sample
(n = 655), linear regression was used to regress
periodontal disease change measures on baseline
25(OH)D (Table 3). Regression coefficients, stan-
dard errors (SEs), and affiliated P values for the
baseline 25(OH)D per each 10-nmol/L increment are
presented. Regression coefficients represent a 1-mm
change in ACH, CAL, or PD or a 1-unit change in the
percent of gingival sites that bled for a 10-nmol/L
difference in 25(OH)D. The authors examined whether
adjustment for common periodontal disease risk
factors, as noted in the literature (Table 2), con-
founded the regression models. A forward selection
process was used where confounder selection was
based on confounders that changed the b-coefficient
‡10%. Multivariable regression models were adjusted
for the following covariates assessed at baseline: age,
education, frequency of dental visits, smoking sta-
tus, self-reported history of diabetes, and current
use of osteoporosis-related medications or bone
therapies (e.g., current use of hormone therapy
drugs, bone drugs [miacalcin, alendronate], or se-
lective estrogen receptor modulator drugs [ralox-
ifene]). Models examining ACH side-by-side change
were also adjusted for baseline whole-mouth mean
ACH. Models examining CAL or PD whole-mouth
mean change were also adjusted for baseline whole-
mouth mean CAL or PD, respectively; models ex-
amining change in the percentage of all gingival
sites in themouth that bled were also adjusted for the
baseline measure of percentage of gingival sites that
bled. Adjustment for baseline measures of peri-
odontal disease helps to differentiate between cross-
sectional and longitudinal relationships. Tests were
Table 1.
Change in Periodontal Disease Measures From Baseline (1997 to 2000) to Follow-Up
(2002 to 2005) Among 655 Participants in the Buffalo OsteoPerio Study Who Had
Baseline Plasma 25(OH)D Concentrations and Attended the Follow-Up Exam
Periodontal Disease Change Measure Mean SD Median Minimum Max
ACH side-by-side mean change (mm) 0.18 0.22 0.16 -0.45 2.90
CAL whole-mouth mean change (mm) -0.17 0.50 -0.19 -1.59 3.23
PD whole-mouth mean change (mm) -0.15 0.39 -0.15 -1.88 2.14
Change in the percentage of gingival sites that
bled on assessment
-21.8 24.0 -19.6 -89.7 77.3
Change measures were calculated by subtracting baseline periodontal disease measures from follow-up periodontal disease measures, with positive values
indicating a greater loss in alveolar bone, clinical attachment, or worsening of PD with time or a greater percentage of gingival sites that bled with time.
** LIAISON 25-OH Vitamin D TOTAL Assay, DiaSorin, Stillwater, MN.
†† SAS for Windows, v.9.3, SAS Institute, Cary, NC.
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Table 2.
Mean and SD of Baseline Plasma 25(OH)D Concentrations by Baseline Characteristics:
The Buffalo OsteoPerio Study (n 5 655)
Baseline Characteristic
Baseline Plasma 25(OH)D
n Mean (SD) P*
Overall sample 655 60.64 (21.9)
Categories of vitamin D status in 25(OH)D (nmol/L) <0.0001
Deficient (<30) 47 22.94 (1.3)
Inadequate (‡30 to <50) 159 41.36 (0.7)
Adequate (‡50 to <75) 300 61.74 (0.5)
Adequate (‡75) 149 90.88 (0.7)
ACH definition of periodontal disease20 0.367
None 175 61.93 (22.4)
Mild/moderate 335 59.45 (20.7)
Severe 145 61.82 (24.1)
CDC/AAP definition of periodontal disease23 0.297
None/mild 145 62.98 (23.6)
Moderate 404 59.70 (21.3)
Severe 106 61.01 (21.9)
Percentage of gingival sites that bled at baseline (%) 0.004
Tertile 1 (0 to 22.2) 223 61.51 (22.3)
Tertile 2 (22.6 to 45.0) 214 63.64 (22.0)
Tertile 3 (45.1 to 100) 218 56.80 (20.9)
Number of teeth at baseline 0.038
6 to 14 51 53.46 (24.8)
15 to 24 227 62.13 (22.7)
25 to 28 377 60.71 (20.9)
Age (years) 0.018
<60 143 64.30 (22.3)
60 to <70 322 60.88 (22.3)
‡70 190 57.47 (20.6)
Race 0.806
White 646 60.66 (21.8)
Other 9 58.85 (28.5)
Education 0.310
High school diploma or equivalent or less 134 58.92 (22.8)
School after high school 521 61.08 (21.7)
Cigarette smoking status 0.598
Never 364 60.25 (22.2)
Former 276 61.38 (21.1)
Current 15 56.25 (30.0)
Waist circumference (cm)† <0.0001
Tertile 1 (61 to 78) 223 68.47 (22.3)
Tertile 2 (79 to 87) 214 60.33 (20.4)
Tertile 3 (88 to 135) 209 52.92 (20.1)
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Table 2. (continued)
Mean and SD of Baseline Plasma 25(OH)D Concentrations by Baseline Characteristics:
The Buffalo OsteoPerio Study (n 5 655)
Baseline Characteristic
Baseline Plasma 25(OH)D
n Mean (SD) P*
Waist-to-hip ratio† <0.0001
Tertile 1 (0.65 to 0.77) 214 66.66 (22.5)
Tertile 2 (0.77 to 0.82) 216 58.43 (18.9)
Tertile 3 (0.82 to 1.20) 215 57.29 (22.9)
BMI (kg/m2) <0.0001
Underweight or normal (<25) 289 67.34 (22.3)
Overweight (25 to <30) 233 58.17 (20.9)
Obese (‡30) 133 50.39 (17.7)
Recreational physical activity (MET hours/week)‡ <0.0001
None 97 53.71 (21.9)
<12.5 275 58.17 (21.1)
‡12.5 283 65.40 (21.7)
Hormone therapy use† 0.035
Never 194 58.25 (23.1)
Past only 116 58.17 (19.9)
Current 338 62.64 (21.4)
Osteoporosis-related medication use or bone therapies§ 0.004
No 288 57.85 (21.6)
Yes 367 62.82 (22.0)
Self-reported history of osteoporosis 0.146
No 573 60.17 (21.8)
Yes 82 63.93 (22.7)
Worst-site T score 0.019
Normal 118 61.26 (21.4)
Low bone density 300 62.85 (21.2)
Osteoporosis 237 57.52 (22.8)
Self-reported history of diabetes 0.009
No 632 61.06 (22.0)
Yes 23 48.90 (15.8)
Days since last dental cleaning† 0.567
£90 254 61.27 (21.4)
>90 386 60.26 (22.4)
Frequency of dental visits 0.017
Never or only with a problem 50 52.47 (20.0)
Once a year 86 59.66 (20.5)
More than once a year 519 61.58 (22.2)
Frequency of flossing teeth† 0.083
Not every week 116 61.51 (23.5)
Once a week 62 62.80 (17.6)
More than once a week 189 57.12 (23.0)
Every day 287 61.90 (21.0)
* P values from analysis of variance of mean baseline plasma 25(OH)D concentrations across level of baseline characteristics.
† Sample size does not add up to 655 due to missing data.
‡ MET, metabolic equivalent task.
§ Current use of osteoporosis-related medications or bone therapies include women taking current hormone therapy drugs, bone drugs (miacalcin,
alendronate), or selective estrogen receptor modulator drugs (raloxifene).
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considered statistically significant with P values of
<0.05 (two-sided).
The multivariable model is also shown with and
without further adjustment for bodymass index (BMI)
and self-reported recreational physical activity, both
of which are strong predictors of vitamin D sta-
tus.26,27 Inclusion of these variables in the model will
explain variation in 25(OH)D and could result in
overadjustment; therefore, the results are presented
with and without their inclusion in the model. The
authors also examined these analyses stratified by
baseline periodontal disease status for ACH, CAL,
and PD change measures and stratified by tertiles of
baseline measures of percentage of gingival sites
that bled on assessment (Table 4). P values for in-
teraction between baseline 25(OH)D and baseline
periodontal disease status were estimated by addi-
tion of an interaction term to the logistic regression
model. P values <0.20 (two-sided) for interactions
were considered statistically significant.
Further, sensitivity analyses were conducted to
explore the effect of teeth lost between baseline and
follow-up. Lost teeth resulted in missing measurements
that could lead to biased estimates of periodontal
disease change. To address this concern, the au-
thors conducted a sensitivity analysis by imputing
a wide range of plausible values (from 2 to 10 mm of
change) to estimate the extent that tooth lossmay have
influenced results for whole-mouth mean change
values.
Further exploratory analyses using linear regres-
sion were also conducted to examine the association
between periodontal disease–change measures and
baseline 25(OH)D among participants with stable
vitamin D status with time [25(OH)D change <20 nmol/L
(n = 422)]. An increase in 25(OH)D concentrations of
20 nmol/L, in the absence of sunlight, requires
a substantial increase in vitamin D intake per day
(1,000 IU/day in supplementation).28,29 Because
two-thirds of the sample did not increase or decrease
their 25(OH)D concentrations beyond 20 nmol/L, the
authors considered women outside this range (–20
nmol/L) to have greatly changed their vitamin D status
with time.
Table 3.
b-Coefficients and SEs for Changes in Periodontal Disease Measures Corresponding to
a 10-nmol/L Difference in Baseline 25(OH) D Concentrations (nmol/L) Among all Women
With Baseline 25(OH)D Measures and Limited to Women With Stable 25(OH)D
Concentrations With Time: The Buffalo OsteoPerio Study
Value
Baseline 25(OH)D (n = 655)
Baseline 25(OH)D Among Participants Who
Changed <20 nmol/L in 5 Years (n = 442)
b-Coefficient (SE) P* b-Coefficient (SE) P*
ACH side-by-side mean change (mm)
Age-adjusted model -0.001 (0.004) 0.724 -0.003 (0.005) 0.579
Multivariable model 1†§ -0.003 (0.004) 0.474 -0.005 (0.006) 0.397
Multivariable model 2‡§ -0.002 (0.004) 0.593 -0.004 (0.006) 0.530
CAL whole-mouth mean change (mm)
Age-adjusted model -0.001 (0.009) 0.889 0.003 (0.012) 0.788
Multivariable model 1† 0.001 (0.008) 0.905 0.005 (0.012) 0.686
Multivariable model 2‡ 0.001 (0.009) 0.882 0.008 (0.012) 0.501
PD whole-mouth mean change (mm)
Age-adjusted model 0.009 (0.007) 0.214 0.013 (0.009) 0.157
Multivariable model 1† 0.0009 (0.006) 0.883 0.006 (0.008) 0.432
Multivariable model 2‡ 0.0005 (0.006) 0.930 0.007 (0.008) 0.429
Change in the percentage of gingival sites
that bled on assessment (%)
Age-adjusted model 0.864 (0.433) 0.046 0.389 (0.572) 0.497
Multivariable model 1† 0.034 (0.281) 0.903 -0.209 (0.366) 0.568
Multivariable model 2‡ 0.112 (0.295) 0.704 -0.155 (0.382) 0.685
* P value for associated b-coefficient.
† Model 1 is adjusted for age, education, frequency of dental visits, smoking status, diabetes status, current use of osteoporosis-related medications or bone
therapies, and baseline periodontal disease measure.
‡ Model 2 is equivalent to model 1, but further adjusted for BMI and recreational physical activity.
§ Analyses for baseline 25(OH)D include only 651 women and analyses for stable 25(OH)D include only 439 women because some women’s cemento-
enamel junctions were not visible on their baseline radiograph to determine baseline whole-mouth mean ACH.
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RESULTS
The authors examined characteristics of women in-
cluded (n = 655) and excluded (n = 265) from these
analyses. Women excluded had slightly lower mean
25(OH)D concentrations (mean [SD] = 58.22 [24.4]
nmol/L) than women included (60.64 [21.9] nmol/L),
although this difference was not statistically signifi-
cant (P = 0.14). A greater percentage of excluded
women had severe periodontal disease based on
measures of ACH and tooth loss due to periodontal
disease (30.2% versus 22.1%, P = 0.03) and the CDC/
AAP definition of periodontal disease (20.0% versus
16.2%, P = 0.25), although these differences were
only statistically significant for disease based on
ACH and tooth loss. Women excluded versus in-
cluded had fewer teeth at baseline (mean [SD] 22.48
[5.5] versus 23.72 [5.0], P = 0.001), were older (68.91
[7.5] versus 65.60 [6.6], P <0.0001), were more likely
to be a race other than white (4.9% versus 1.4%,
P = 0.002), were more likely to be current smokers at
baseline (5.3% versus 2.3%, P = 0.01), and were more
likely to have osteoporosis at baseline (42.6% versus
36.2%, P = 0.03) and self-reported diabetes at baseline
(6.8% versus 3.5%, P = 0.03). Statistically significant
differences with respect to baseline measures of per-
centage of gingival sites that bled, education, BMI,
waist circumference, recreational physical activity,
hormone therapy use, current use of osteoporosis-
related medications or bone therapies, and measures
of dental hygiene were not observed (data not shown).
Summaries of the changes in periodontal disease
measures during 5 years are shown in Table 1. The
mean ACH side-by-side change indicates loss, on
average, in alveolar bone with time. For the other
periodontal disease–change measures based on
CAL, PD, and gingival bleeding, mean changes were
negative, suggesting that on average, there was
a slight improvement in these measures with time.
Table 4.
Adjusted b-Coefficients and SEs for Changes in Periodontal Disease Measures
Corresponding to a 10-nmol/L Difference in Baseline 25(OH)D Concentrations (nmol/L)
Stratified by Baseline Periodontal Disease Status (n 5 655): The Buffalo OsteoPerio
Study
Value n b-Coefficient (SE) P*
ACH side-by-side mean change (mm)†
None 175 0.003 (0.004) 0.473
Moderate 332 -0.0009 (0.005) 0.857
Severe 144 -0.012 (0.014) 0.385
P for interaction 0.319
CAL whole-mouth mean change (mm)
None/Mild 145 -0.014 (0.013) 0.286
Moderate 404 0.010 (0.011) 0.354
Severe 106 -0.037 (0.030) 0.219
P for interaction 0.317
PD whole-mouth mean change (mm)
None/Mild 145 -0.007 (0.010) 0.531
Moderate 404 0.005 (0.007) 0.517
Severe 106 -0.026 (0.024) 0.291
P for interaction 0.586
Change in the percentage of gingival sites that bled on
assessment (%)
Tertile 1 (0 to 22.2) 223 -0.468 (0.431) 0.279
Tertile 2 (22.6 to 45.0) 214 0.516 (0.509) 0.312
Tertile 3 (45.1 to 100) 218 0.417 (0.617) 0.500
P for interaction 0.542
Models are adjusted for age, education, frequency of dental visits, smoking status, diabetes status, current use of osteoporosis-related medications or bone
therapies, baseline periodontal disease measures, BMI, and recreational physical activity. Periodontal disease status is defined using the whole-mouth mean
ACH and self-reported tooth loss due to periodontitis20 when analyzing the ACH side-by-side mean change measures. Periodontal disease status is defined
using CDC/AAP defined categories23 when analyzing the CAL and PD whole-mouth mean change measures. Change in the percentage of gingival sites that
bled on assessment is stratified by tertiles of percent of gingival sites that bled at baseline.
* P value for associated b-coefficient.
† Analyses include only 651 women because four women’s cemento-enamel junctions were not visible on their baseline radiograph to determine baseline
whole-mouth mean ACH.
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At baseline, 25(OH)D concentrations ranged
from 5.91 to 146.01 nmol/L with 7% (n = 47) of the
sample having deficient [25(OH)D <30 nmol/L] and
24% (n = 159) having inadequate [25(OH)D <50 nmol/L]
vitamin D status30 (Table 2). Mean baseline 25(OH)D
concentrations did not vary significantly by baseline
periodontal disease status as defined using the ACH
or CDC/AAP categorical definitions. Twenty-two per-
cent of women were defined as having none/mild
and 16% severe periodontal disease at baseline
based on the CDC/AAP definition. The majority of
the sample (62%) had moderate disease. Mean
baseline 25(OH)D concentrations were lower among
women with a greater percentage of gingival sites
that bled at baseline (tertile 3) compared with
women with fewer sites that bled (tertile 1) and
among women with fewer compared to more teeth
at baseline. Mean 25(OH)D concentrations were
lower for older women (‡70 years) and women with
greater waist circumferences, waist-to-hip ratios,
and BMIs and women who self-reported not en-
gaging in recreational physical activity. Mean con-
centrations were also lower for women who reported
never using hormone therapy or using it in the past,
and concentrations were lower in women who did
not take osteoporosis-related medications or bone
therapies. Women who had osteoporosis by dual
x-ray absorptiometry or self-reported a history of
diabetes also had lower 25(OH)D concentrations, as
did women who never frequented the dentist or went
only with a problem.
Table 3 shows regression coefficients and standard
errors (SEs) for change in periodontal disease mea-
sures regressed on baseline 25(OH)D. In the age-
adjusted model, only change in the percentage of
gingival sites that bled on assessment was associated
with 25(OH)D status. A 10-nmol/L greater baseline
25(OH)D concentration was associated with 0.9
percentage points more gingival sites that bled at
follow-up than at baseline (P = 0.046). Adjustment for
additional covariates attenuated this association
(Model 1 b-coefficient [SE] = 0.034 [0.281], P = 0.903).
There were no other statistically significant associ-
ations observed between baseline 25(OH)D and
change in any other periodontal disease measure.
Among the 655 women in these analyses, 6.7%
(n = 24) self-reported loss of ‡1 tooth due to peri-
odontal disease. Imputing 2, 5, or 10 mm for ACH,
CAL, and PD change measures for teeth lost because
of periodontal disease during follow-up did not greatly
influence the results. The 25(OH)D b-coefficients
(SEs) and P values for Model 2 with a 10-mm im-
putation were: -0.007 (0.008), P = 0.381 for ACH;
0.004 (0.011), P = 0.722 for CAL; and 0.002 (0.009),
P = 0.803 for PD. Table 3 also shows exploratory
analyses where the analyses of baseline 25(OH)D
were restricted to include only participants whose vi-
tamin D status was stable with time (change <20 nmol/L
from baseline to follow-up). This slightly strengthened
the b-coefficients when examining change measures
for ACH, CAL, and PD. The b-coefficient in the model
examining change in the percentage of gingival
sites that bled became negative. Even so, vitamin D
status remained unrelated to periodontal disease
progression.
Table 4 shows associations between baseline
25(OH)D and periodontal disease change measures
stratified by baseline periodontal disease status.
Among women with severe periodontal disease at
baseline, greater concentrations of baseline 25(OH)D
were consistently associated with less periodontal
disease progression defined using measures of ACH,
CAL, and PD, but these associations were not statis-
tically significant.
DISCUSSION
This is the largest prospective study to date on
vitamin D status and progression of periodontal
disease in postmenopausal women. The authors
observed no associations between vitamin D status,
assessed with baseline 25(OH)D concentrations and
subsequent 5-year change in periodontal disease
measures inclusive of changes in ACH, CAL, PD, and
gingival bleeding. These results did not vary greatly
by baseline periodontal disease status. There was
some suggestion that among women with severe
periodontal disease at baseline, higher baseline
25(OH)D concentrations may protect against peri-
odontal disease progression, defined using ACH,
CAL, and PD, but these results were not statistically
significant. The authors cannot say for certain that
the results differed by baseline disease severity.
Additionally, these results do not support the pre-
vious cross-sectional findings in the same cohort of
women7 where adequate compared to inadequate or
deficient vitamin D status was associated with de-
creased odds of periodontal disease.
Among the 655 participants, 16.2% and 61.7% of
the sample had severe and moderate periodontal
disease, respectively, at baseline (1997 to 2000).
This is comparable to recent estimates of 11.7%
(aged 50 to 64 years) and 11.2% (aged ‡65 years) of
United States adults with severe disease and 37.7%
(aged 50 to 64 years) and 53.0% (‡65 years) of
United States adults with moderate disease as re-
ported using nationally representative data.1 Although
the baseline prevalence estimates of periodontal dis-
ease are comparable to national prevalence esti-
mates, previous data from the cohort showed small
changes in periodontal disease measures during 5
years.21 The authors speculated that this was attrib-
utable to a low prevalence of periodontal disease risk
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factors (e.g., minimal current smokers, low prevalence
of diabetes) in this cohort of postmenopausal women.21
It is possible that the null results are explained by the
minimal progression of disease during 5 years (e.g.,
0.18-mm loss in alveolar bone on average). Perhaps
a longer follow-up period is needed to observe
meaningful changes in disease status. A previous
report of disease progression during 10 years cites
0.7 to 1.4 mm of alveolar bone loss among in-
dividuals 25 to 65 years old at baseline and 2.8 mm
among those 60 to 70 years old.31
The null results are not likely explained by a lack of
variation in vitamin D status. In the sample, 7% of
women demonstrated deficient baseline vitamin D
status [i.e., 25(OH)D <30 nmol/L]. This is similar to
the 3% to 5% of older women reported to have de-
ficient vitamin D status [defined as 25(OH)D <25
nmol/L] in a nationally representative dataset32 in
which associations between vitamin D status and
clinical measures of periodontal disease have been
observed.10,11
Two previously conducted studies14,17 examined
associations between vitamin D intake and repeat
measures of periodontal disease with time. Garcia
et al.14 conducted a 12-month study among 51 pa-
tients in a periodontal disease maintenance program
consisting of postmenopausal women and men 50
to 80 years old. They showed that supplement users,
defined as users of both calcium (‡ 1,000 mg/day)
and vitamin D (‡400 IU/day) supplements for >18
months at baseline, had borderline statistically
significant (P = 0.058) better periodontal disease
measures (assessed collectively as attachment loss,
bleeding on probing, gingival index, PD, and furca-
tion involvement) at 12months than non-supplement
users (who did not use vitamin D or calcium sup-
plements and had low dietary intake of these nutri-
ents). Supplement users, although not different with
respect to ACH from non-users, had denser oral bone
at 6 and 12 months. Follow-up in this study design
was short, and supplement users of calcium were not
examined differently from users of vitamin D. In the
Department of Veterans Affairs Dental Longitudinal
Study of men (mean age 62.9 years), vitamin D
intake of ‡800 compared to <400 IU/day was asso-
ciated with a respective 33% and 46% decreased
odds of severe periodontal disease, defined with
measures of CAL and PD, and moderate-to-severe
disease, defined using measures of alveolar bone
loss.17 Data collected on diet and periodontal disease
one to four times from 1986 to 1998 was used in
a repeated-measures cross-sectional design. Neither
of these studies examined progression of disease
over time in relation to vitamin D intake.
In a different study conducted by Krall,15 in men
aged ‡65 years, high compared to low dietary plus
supplemental calcium, but not vitamin D intake, was
shown to protect against the 7-year progression of
periodontal disease as defined by alveolar bone loss.
It is possible that the null results with vitamin D intake
were explained in part by misclassification of vitamin
D status when using the measure of oral vitamin D
intake,26 or their results support what the present
authors observed, i.e., that vitamin D status is not
associated with changes in alveolar bone loss. It is
also possible that vitamin D intake is influential, but
only among persons with low sun exposure, which
is not explored in this study. Differently, Jimenez
et al.18 observed a lower incidence of self-reported
tooth loss and periodontitis in a 20-year prospective
cohort of 42,730 male health professionals with high
compared to low predicted 25(OH)D concentra-
tions. The multivariable model was adjusted for age,
smoking, pipe use, chewing tobacco use, multivi-
tamin use, vitamin E, vitamin C, dental profession,
alcohol consumption, routine physical examination,
and diabetes status. After further adjustment for BMI,
race, and physical activity [factors used to develop
the 25(OH)D predictor score], the periodontitis, but
not the tooth loss, association was no longer sta-
tistically significant. This model may have been
overadjusted, or as the authors suggested, self-re-
ported periodontitis compared to self-reported tooth
loss may be more susceptible to misclassification
and led to the attenuation of the observed associ-
ation. The predictor score may also reflect a healthy
lifestyle score rather than a true indicator of vitamin
D status. In a third study, a 3-year randomized
clinical trial of combined vitamin D and calcium
supplementation, a protective effect of supple-
mentation on tooth loss was observed.16 Un-
fortunately, that study cannot differentiate the effect
of one nutrient from another. It is also possible that
the difference between Krall’s and Jimenez et al.’s
study findings compared to others could be explained
by the outcome of tooth loss, which is representative
of end-stage periodontal disease compared to in-
cident periodontitis or changes in PD, CAL, ACH,
and gingival bleeding.
Whether the present results are generalizable to
other populations remains unknown. The study
consists of well-educated, primarily white women. It
is possible that loss of participants due to follow-up
may have contributed to the null results because
women who were excluded from the current anal-
yses had slightly lower 25(OH)D concentrations
and more severe periodontal disease. It is also
questionable whether the follow-up period was long
enough; however, this study is still the largest and
longest prospective analysis of vitamin D status
and periodontal disease progression in postmeno-
pausal women. The participants all had standardized
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full-mouth oral exams and oral radiographs at
baseline and follow-up. The authors were able
to assess change in a varied set of periodontal
disease measures using matched sites at both time
points.
CONCLUSIONS
The results of the present study suggest that baseline
plasma vitamin D status does not influence the
subsequent 5-year change in chronic periodontal
disease measures in postmenopausal women. Thus,
supplementation of vitamin D for prevention of
periodontal disease progression is not warranted at
this time. Further replication of these findings is
needed. The authors recommend that these associ-
ations be examined in studies with a longer follow-up
period of periodontal disease progression.
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